Gossamer Bio (NASDAQ:GOSS) Posts Earnings Results, Misses Estimates By $0.03 EPS

Gossamer Bio (NASDAQ:GOSS) posted its quarterly earnings data on Friday. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03), FiscalAI reports. The company had revenue of $16.96 million for the quarter, compared to analysts’ expectations of $4.67 million.

Gossamer Bio Price Performance

Shares of GOSS traded up $0.01 during midday trading on Friday, reaching $0.34. The stock had a trading volume of 5,500,862 shares, compared to its average volume of 12,326,179. Gossamer Bio has a 1-year low of $0.31 and a 1-year high of $3.87. The company’s fifty day simple moving average is $0.40 and its two-hundred day simple moving average is $1.84. The company has a market cap of $79.80 million, a price-to-earnings ratio of -0.45 and a beta of 2.15.

Gossamer Bio News Summary

Here are the key news stories impacting Gossamer Bio this week:

• Negative Sentiment: Multiple law firms filed or publicized securities class-action claims against Gossamer Bio over allegations tied to the failed PROSERA study, highlighting legal overhang and potential damages risk for shareholders. Article: Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– Hagens Berman
• Negative Sentiment: Law firms including Schall, Pomerantz, Rosen, Gross, Faruqi & Faruqi, and Bronstein are urging investors to join or lead the lawsuit, reinforcing concerns that the stock faces ongoing litigation risk and distraction. Article: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
• Neutral Sentiment: Gossamer Bio said it will report first-quarter 2026 financial results and host a conference call on May 18, which may provide new guidance on cash runway, pipeline priorities, and management’s response to the trial setback. Article: Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Wall Street Zen cut shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. The Goldman Sachs Group cut shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Oppenheimer decreased their price target on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a research report on Tuesday, April 21st. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.43.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Gossamer Bio by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock valued at $31,586,000 after purchasing an additional 598,981 shares in the last quarter. State Street Corp raised its holdings in shares of Gossamer Bio by 139.7% in the 4th quarter. State Street Corp now owns 9,310,969 shares of the company’s stock valued at $28,864,000 after purchasing an additional 5,427,302 shares in the last quarter. Geode Capital Management LLC raised its stake in Gossamer Bio by 3.9% during the 4th quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock worth $15,109,000 after acquiring an additional 183,183 shares in the last quarter. Corient Private Wealth LLC raised its stake in Gossamer Bio by 19,123.7% during the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after acquiring an additional 3,825,879 shares in the last quarter. Finally, Millennium Management LLC raised its stake in Gossamer Bio by 629.3% during the 3rd quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock worth $9,519,000 after acquiring an additional 3,123,081 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.